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CASE REPORT
INTRODUCTION
Bariatric surgery is the most effective option to treat
morbid obese patients and the number of patients under-
going these kind of surgeries is increased with 11% in
2013 when compared with 2008. In the Netherlands the
number of bariatric surgeries almost doubled in these
years; from 3,500 in 2008 to 6,807 in 2013.1,2 This is among
others explained by the fact that obesity has worldwide
doubled since 1980 and it is estimated that 39% of the
world's adult population is overweight [Body Mass Index
(BM) t 25] and 13% is obese (BMI t 30).3
The goal of bariatric surgery is to decrease the intake
of food and absorption of nutrients for severely obese pa-
tients, resulting in weight loss.4 As the gastrointestinal
(GI) tract is substantially altered by these surgeries, drug
absorption of orally administered drugs can also be al-
tered. Little is known about the effects of a bariatric sur-
gery on drug exposure and the effect of the surgery on
the exposure of drugs is hard to predict. For example,
gastric pH rises which could cause increased absorption
of drugs soluble in higher pH ranges or decreased ab-
sorption of drugs soluble in low pH ranges. In addition,
absorption could decrease, as the transit time of a drug
through the GI tract is reduced. Also, the limited food in-
take of patients that underwent bariatric surgery alters
absorption.
Direct-acting antivirals (DAAs) are highly effective
drugs licensed for the treatment of chronic hepatitis C vi-
rus (HCV) infection. Combinations of at least two DAAs
are used and over 90% of the patients is cured after 8 to 12
weeks of treatment. Treatment duration can be prolonged
to 24 weeks, or ribavirin can be added to enhance the po-
tency of the regimen when a patient is difficult to treat.
This includes patient that are treatment-experienced, have
genotype 1a or 3, or have (decompensated) cirrhosis.5
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A B S T R A C T
Chronic hepatitis C virus (HCV) infection can be cured with treatment using direct-acting antivirals (DAAs). Although these drugs
have been widely studied, information about certain special populations is missing. In this case report we describe a treatment-expe-
rienced patient with chronic HCV infection genotype 1b, treated with 150 mg/day simeprevir, 400 mg/day sofosbuvir, and 1,000 mg/
day ribavirin for 24 weeks, after a Roux-and-Y gastric bypass. At steady-state a pharmacokinetic curve was recorded of sofosbuvir,
GS-331007, and simeprevir. Ribavirin trough plasma concentration (Ctrough) was determined. The simeprevir area under the-concen-
tration time curve (AUClast) and Ctrough were 9.42 h.mg/L and 0.046 mg/L, respectively. Compared to what was described in the liter-
ature, simeprevir exposure was low and therefore the simeprevir dose was increased to 300 mg/day. The increased dose of
simeprevir was well tolerated and Ctrough was 0.532 mg/L. Sofosbuvir AUClast and Ctrough were 0.63 h.mg/L and 0.0013 mg/L. GS-
331007 AUClast and Ctrough were 21.02 h.mg/L and 0.35 mg/L. Ribavirin Ctrough was 2.5 mg/L. Sofosbuvir, GS-331007, and ribavirin
exposure were comparable with levels described in literature. The patient achieved a sustained virological response twelve weeks af-
ter the completion of treatment.
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The influence of bariatric surgery on direct-acting anti-
virals (DAAs) is unknown, but it is previously described
that the absorption of DAAs daclatasvir, simeprevir, parit-
aprevir, ombitasvir, and dasabuvir are, just as ribavirin, al-
tered when taken together with food.6-9 In addition, the
solubility of daclatasvir, ledipasvir and velpatasvir is de-
pendent on gastric pH.6,10,11 Therefore, it is likely that bari-
atric surgery alters exposure of DAAs; possibly causing
increased (toxicity) or decreased (sub therapy) plasma
concentrations.
In this case report we describe efficacy, safety, and
pharmacokinetics of a patient who underwent bariatric
surgery and who, after relapsing to previous DAA therapy,
was successfully treated for HCV-infection genotype 1b
with sofosbuvir, simeprevir, and ribavirin.
CASE REPORT
We describe a 61-year old Brazilian female patient who
presented to our outpatient clinic in 2011 with chronic
HCV genotype 1b infection. She was diagnosed with
HCV-infection in 2008, but the transmission route was
unknown. Possible sources of infection included dental
treatment or a caesarean section in Brazil.
The patient was severely obese with a BMI of 35.4 kg/
m2 (weight 84 kg, height 1.54 m). Ultrasound demonstrat-
ed hepatic steatosis without any ultrasonographic signs of
cirrhosis. Evaluation of liver stiffness using Fibroscan®14,15
showed a value of 13.6 kPa, consistent with METAVIR fi-
brosis score F3 (severe fibrosis).16,17 A liver biopsy showed
moderately active periportal inflammation and moderate
periportal fibrosis with formation of septae in less than
50% of portal fields (METAVIR score A2/F2-3) and mac-
rovesicular steatosis in 40-50% of hepatocytes with mini-
mal pericellular fibrosis (Brunt score steatosis grade 2,
fibrosis stage F1).18 Laboratory testing showed mildly ele-
vated liver enzymes with an ALT of 77 U/L, AST of 51 U/L
and gamma-GT of 57 U/L. Serum bilirubin, prothrombin
time, albumin, creatinine, thrombocytes, and fasting blood
glucose values were all normal. HCV RNA was 9.56 x 105
IU/mL and HBsAg and anti-HIV 1 & 2 antibodies were
negative.
The patient was a non-responder to treatment with
peg-interferon alfa and ribavirin in 2009. In 2013, she was
included in a clinical trial and was treated with DAAs da-
clatasvir and asunaprevir for 24 weeks. A relapse occurred
after this treatment.
Whilst waiting for registration and reimbursement of
the first DAAs in the Netherlands the patient decided to
undergo gastric bypass surgery in 2014 (Roux-and-Y gas-
tric bypass). She came back to our outpatient clinic in 2015
for (re-) treatment of the chronic HCV-infection. Her
weight had reduced to 59 kg (BMI 24.9 kg/m2), and
transaminases had improved (ALT 48 U/L; AST 39 U/L).
All other liver enzymes and liver function tests were not
altered. HCV RNA load was 5.64 x 106 IU/mL and Fibro-
scan® showed a value of 7.8 kPa. Sequencing of the viral
genome was performed on the regions NS5A and NS3 (as
she had received a NS5A inhibitor and a Protease Inhibi-
tor), which showed a high level of resistance associated
substitutions (RAS) to NS5A inhibitors on the loci L31M/
I and Y93H. There were no RAS present in the NS3 gene
of the viral genome. For these reasons, we decided to treat
the patient with 400mg sofosbuvir once daily (Sovaldi®,
Gilead Sciences, Cambridge, United Kingdom), 150mg
simeprevir once daily (Olysio®, Janssen-Cilag Interna-
tional, Beerse, Belgium), and 1000 ribavirin per day, for a
total of 24 weeks.19-21
Simeprevir and ribavirin in particular must be taken
with food for adequate plasma concentrations.7 However,
due to the bariatric surgery, the patient was not able to eat
large meals. To study the exposure of the DAAs and ribavi-
rin in this patient, a pharmacokinetic curve was obtained
at Week 3 of DAA treatment. Blood was sampled at t = 0
(pre-dose), 2, 3, 5, 6, 8, and 24 h after intake of the DAAs.
DAA plasma concentrations were determined using an in-
house made, validated high performance liquid chroma-
tography (HPLC)-tandem mass spectometry (MS/MS)
assay. Pharmacokinetic parameters were calculated using
WinNonlin/Phoenix version 6.3, Pharsight Corporation,
St. Louis, MO, USA. The assay lower limits of quantifica-
tion for sofosbuvir, GS-331007 and simeprevir were 2.5 ng/
mL, 10 ng/mL, and 10 ng/L respectively. The precision for
low, medium and high quality control (QCs) samples was
< 10% for all analytes. Ribavirin plasma concentrations
were determined using validated HPLC assay with Ultra-
violet detection.22,23
At Week 3, the area under the concentration-time curve
(AUClast) for sofosbuvir was 0.63 h•mg/L, the maximum
plasma concentration (Cmax) was 0.35 mg/L, and the mini-
mum plasma concentration (Ctrough) was 0.0013 mg/L. For
the main inactive metabolite of sofosbuvir, GS-331007, the
AUC0-24 was 21.02 h•mg/L, Cmax was 1.55 mg/L, and the
Ctrough was 0.35 mg/L (Figure 1A).
For simeprevir, at Week 3 of treatment, the AUC0-24
was 9.42 h•mg/L, the Cmax was 1.21 mg/L, and the Ctrough
was 0.046 mg/L (Figure 1B). Ribavirin concentration was
2.5 mg/L. Sofosbuvir and ribavirin concentrations were
considered adequate but simeprevir concentrations were
sub therapeutic compared with those described in litera-
ture.24 As a result, at Week 10 of treatment, the simeprevir
dose was doubled to 150 mg twice daily (taken together
with food). At Week 14 trough concentrations of ribavirin
and simeprevir were determined again and were 0.532 mg/
L and 3.5 mg/L, respectively. The hemoglobin concentra-
ton had dropped from 12.3 g/dL to 9.8 g/dL.
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HCV RNA was undetectable during treatment at Week
3, 4, 12, 24 (end of treatment) and 12 weeks after end of
treatment (sustained virological response, SVR12).
During treatment, the main side effect was extreme fa-
tigue. Liver enzymes, liver function tests and renal func-
tion were all normal during treatment. Twelve weeks after
completion of treatment Fibroscan® showed a value of 4.6
kPa.
For this case report no formal ethical approval was ob-
tained as all procedures were performed for regular health
care purposes. The patient did not have to comply to cer-
tain extra examinations of life style rules. However, the
patient gave consent for performing the pharmacokinetic
curve and publication of this paper. This was recorded in
the patient chart.
DISCUSSION
We are the first to describe a patient who was success-
fully treated with DAAs including an adjusted dose of
simeprevir after undergoing gastric bypass surgery. Al-
though simeprevir was not deemed to be ideal in this pa-
tient, given the food-dependent uptake, there was no
alternative choice due to existing resistance to NS5A in-
hibitors.
We treated the patient for 24 weeks, according to na-
tional and international guidelines, as she relapsed to earli-
er dual NS3/NS5A DAA therapy.19-21 We also tried to
enhance the potency of the treatment by adding ribavirin
(at a weight-based dose).
According to the simeprevir label, the AUC increases
by 60% when administered with a fatty meal or normal
breakfast.7 We measured simeprevir Ctrough levels that
were 97% lower than comparable reference values, and the
AUC0-24 was 84% lower. Our patient was not able to have
large or “normal sized” meals (i.e. a high intake of calo-
ries) anymore and we postulate that this resulted in the ex-
tremely low exposure to simeprevir. Despite the fact that
HCV RNA was undetectable at that time, we doubled the
dose of simeprevir to increase the plasma exposure and
possibly efficacy. This dose was well-tolerated and the
Ctrough plasma concentration at Week 14 (4 Weeks after
doubling the dose), was approximately 11-fold higher than
the Week 3 Ctrough level (62% lower than the reference val-
ue). This extreme increase is the result of the non-linear
pharmacokinetics of simeprevir.
For ribavirin, we strived to attain a plasma concentra-
tion of 2.0-3.0 mg/L at steady-state.25 At Week 3 of treat-
ment the plasma concentration was already 2.5 mg/L,
which is remarkable as the patient had a low intake of
a) Sofosbuvir concentrations at Week 3: Ctrough: 0.001 mg/L; Cmax: 0.35 mg/L; Tmax: 2.25 h; AUClast: 0.63 h•mg/L; T1/2: 0.5 h. GS-331007: Ctrough:
0.35 mg/L; Cmax: 1.55 mg/L; Tmax: 4.91 h; AUC0-24: 21.02 h•mg/L. T1/2: 10.3 h. Sofosbuvir reference values (400 mg once daily treatment-naïve
HCV genotype 1-infected subjects without cirrhosis). Sofosbuvir: Tmax: 0.5-1.5 h; Cmax: 0.55 mg/L; AUC0-tau 1.03 h•mg/L. GS-331007: Tmax: 2-4 h;
Cmax: 582 mg/L; AUC0-tau 7.12 h•mg/L.
27
b) Simeprevir concentrations at Week 3: Ctrough: 0.046 mg/L; Cmax: 1.20 mg/L; Tmax: 3.25 h; AUC0-24: 9.41 h•mg/L; T1/2 4.6 h. Week 14: Ctrough:
0.532 mg/L. Simeprevir reference values (treatment experienced patients 150 mg, once daily): Ctrough: 1.41 mg/L; Cmax: 4.38 mg/L; Tmax: 2.03-
9.87 h; AUC0-24: 57.4 h•mg/L.
24
AUClast: area under the concentration-time curve from zero to last sampling time. AUC0-24: area under the concentration-time curve from 0 to 24 h.
Cmax: maximum plasma concentration. Ctrough: trough plasma concentration. Tmax: time to reach maximum plasma concentration. T1/2: elimination
half-life.
Figure 1. Plasma concentrations of 400 mg sofosbuvir once daily and GS-331007 (A) and 150 and 300 mg simeprevir once daily (B).
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food.9 These high ribavirin levels caused anemia and the
patient suffered from extreme fatigue. It was considered
to lower the dose of ribavirin, but because the hemoglob-
in levels remained stable throughout the whole course of
treatment and the patient did not want a dose reduction, so
the starting dose of 1,000 mg/day was continued. The high
plasma concentrations of ribavirin (compared to the low
plasma concentrations of simeprevir) could also be related
to the low body weight of < 60 kg of the patient after gas-
tric bypass surgery. The fact that a large or “normal” meal
could not be consumed seems less important for an ade-
quate ribavirin level as the initial dose was already rela-
tively high.
Sofosbuvir pharmacokinetics were not affected by the
gastric bypass or the low intake of food as the exposure to
both sofosbuvir and GS-331007 (the main inactive metab-
olite of sofosbuvir) were sufficient. This was as expected
because it was earlier described that a high-fat meal does
not influence the plasma concentration of sofosbuvir or
GS-331007.26
This case report describes a patient with chronic
HCV-infection genotype 1b without liver cirrhosis, but
with a relapse after earlier dual DAA-treatment, who was
successfully treated with simeprevir, sofosbuvir, and riba-
virin for 24 weeks after undergoing gastric bypass surgery.
Adequate sofosbuvir and ribavirin plasma concentrations
were achieved, however, simeprevir plasma concentra-
tions were low when simeprevir was dosed according to
the drug label (150 mg once daily).7 Both bariatric surgery
and low intake of food can influence drug absorption and
drug exposure. Awareness is needed when patients who
underwent bariatric surgery are treated with certain drugs
without any experience in this specific condition. This is
especially the case for simeprevir, as absorption is de-
pendent of food intake, it has non-linear pharmacokinetics
and possibly more severe side effects when given in high
dosages. Patients with a history of bariatric surgery who
are treated with simeprevir should be closely monitored
using, for example, therapeutic drug monitoring.
ABBREVIATIONS
• AUClast: area under the concentration-time curve
from zero to last sampling time.
• AUC0-24: area under the concentration-time curve
from 0 to 24 hours.
• BMI: body mass index.
• Cmax: maximum plasma concentration.
• Ctrough: trough plasma concentration.
• DAAs: direct-acting antivirals.
• GI: gastrointestinal.
• HCV: hepatitis C virus.
• PI: protease inhibitor.
• RAS: resistance associated substitutions.
• SVR12: sustained virological response.
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